<SEC-DOCUMENT>0001144204-17-053237.txt : 20171019
<SEC-HEADER>0001144204-17-053237.hdr.sgml : 20171019
<ACCEPTANCE-DATETIME>20171019162306
ACCESSION NUMBER:		0001144204-17-053237
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171019
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171019
DATE AS OF CHANGE:		20171019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		171144957

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv477279_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT PURSUANT<BR>
TO SECTION 13 OR 15(D) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Date
of report (Date of earliest event reported):</FONT> October 19, 2017</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ABEONA THERAPEUTICS INC.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><B><U>Delaware</U></B></TD>
    <TD STYLE="width: 34%; text-align: center"><B><U>001-15771</U></B></TD>
    <TD STYLE="width: 33%; text-align: center"><B><U>83-0221517</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of<BR>
incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3333 Lee Parkway, Suite 600</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dallas, TX 75219</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices) (Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(214)-665-9495</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s telephone number, including area code)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;&nbsp;&nbsp;Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 8.01. Other Events</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 19, 2017, Abeona Therapeutics Inc. issued a press
release entitled &ldquo;Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters&rsquo; Option
to Purchase Additional Shares&rdquo;. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.01 Financial Statements and Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) The following exhibits are being filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 16%"><B><U>Exhibit No.</U></B></TD>
    <TD STYLE="width: 84%"><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv477279_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="text-align: justify"><A HREF="tv477279_ex99-1.htm" STYLE="-sec-extract: exhibit">Press release dated October 19, 2017, entitled &ldquo;Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters&rsquo; Option to Purchase Additional Shares&rdquo; </A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Abeona Therapeutics Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Stephen B. Thompson</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen B. Thompson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President Finance</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Accounting Officer&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 19, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv477279_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="abeo_logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Announces Closing of $92 Million Underwritten
Public Offering and Full Exercise of Underwriters&rsquo; Option to Purchase Additional Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW YORK<FONT STYLE="background-color: white">,
NY and&nbsp;CLEVELAND,&nbsp;OH &ndash; O</FONT>ctober 19, 2017<FONT STYLE="background-color: white">&nbsp;</FONT></B>--&nbsp;Abeona
Therapeutics Inc. <FONT STYLE="background-color: white">(Nasdaq:ABEO), </FONT>a leading clinical-stage biopharmaceutical company
focused on developing novel gene and cell therapies for life-threatening rare diseases, <FONT STYLE="background-color: white">today
announced the </FONT>closing of its underwritten public offering <FONT STYLE="background-color: white">with a gross offering size
of approximately $92 million, </FONT>which includes the full exercise of the underwriters&rsquo; option to purchase 750,000 additional
shares, at the public offering price of $16.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jefferies LLC&nbsp;acted as lead book-running
manager for the offering and RBC Capital Markets as joint book runner. &nbsp;Cantor Fitzgerald &amp; Co. acted as lead manager.&nbsp;
FBR Capital Markets &amp; Co., H.C. Wainwright &amp; Co., JonesTrading Institutional Services LLC and Maxim Group LLC were
co-managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above were offered
pursuant to a shelf registration statement on Form S-3 (File No. 333-205128) that was filed with the&nbsp;Securities and Exchange
Commission&nbsp;(the &ldquo;SEC&rdquo;) on&nbsp;June 22, 2015&nbsp;and that was declared effective by the&nbsp;SEC&nbsp;on&nbsp;July
23, 2015. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the
registration statement. The preliminary prospectus supplement and the accompanying prospectus supplement that form a part of the
registration statement has been filed with the&nbsp;SEC&nbsp;and is available on the&nbsp;SEC&rsquo;s&nbsp;website at&nbsp;www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by request at&nbsp;Jefferies,&nbsp;Attention
Equity Syndicate Prospectus Department,&nbsp;520 Madison Avenue, 2nd Floor,&nbsp;New York, NY&nbsp;10022, via telephone at (877)
821-7388, or email at:&nbsp;<U>Prospectus_Department@Jefferies.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>The securities
described above have not been qualified under any state blue sky laws. This press release does not constitute an offer to sell
or the solicitation of offers to buy any securities of Abeona being offered, and shall not constitute an offer, solicitation or
sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">About Abeona: Abeona Therapeutics Inc.
is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona&rsquo;s lead
programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA)
and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101
(AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202
(AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi
anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases.
In addition, Abeona has a proprietary vector platform, AIM&trade;, for next generation product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B><BR>
Christine Silverstein<BR>
Vice President, Investor Relations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)786-6212<BR>
<U>csilverstein@abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Lynn Granito<BR>
Berry &amp; Company Public Relations&nbsp;&nbsp;<BR>
+1 (212) 253-8881&nbsp;&nbsp;<BR>
<U>lgranito@berrypr.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>This press
release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as
amended, and that involve risks and uncertainties. These statements include, without limitation, statements regarding our anticipated
offering, anticipated use of proceeds and plans and prospects for Abeona, and other statements including the words &ldquo;may,&rdquo;
will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; expect,&rdquo; &ldquo;intend,&rdquo; and
similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute
and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties related to market conditions and the completion
of the public offering on the anticipated terms, or at all, continued interest in our rare disease portfolio, the ability to develop
our product candidates and technologies, the impact of changes in the financial markets and global economic conditions, and other
risks as are set forth in the Company&rsquo;s Annual Report on Form 10-K and other reports filed by the Company with the Securities and
Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in
this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result
of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>abeo_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 abeo_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I (4# 2(  A$! Q$!_\0
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M[D C&3ZGG-3=*-KWU*LW*]K:'+_"W1=.M_ >FW26D)N+B,O+,R NQW$#D]@
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MMITCCC<+N ,:-SM)!Y8UD>']0UG48[2ZN);GRI6)8+# (\9/??NQ^&:V]/\
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L'5+FW57 )89S&Q!!V^Q&#ZT5R?P4_P"0+J7_ %V7^1HJ*B49-%TVY13/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
